THERALASE TECHNOLOGIES INC (TLT.CA) Stock Price, Forecast & Analysis
Canada - TSX-V:TLT - CA88337V1004 - Common Stock
TLT.CA Key Statistics, Chart & Performance
The current stock price of TLT.CA is 0.205 CAD. In the past month the price increased by 5.13%. In the past year, price decreased by -28.7%.
TLT.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| PRN.CA | PROFOUND MEDICAL CORP | N/A | 272.59M | ||
| MIR.CA | MEDMIRA INC | N/A | 56.87M | ||
| CNVI.CA | CONAVI MEDICAL CORP | N/A | 47.59M | ||
| PINK.CA | PERIMETER MEDICAL IMAGING AI | N/A | 27.32M | ||
| ASG.CA | AURORA SPINE CORP | N/A | 23.17M | ||
| NSCI.CA | NANALYSIS SCIENTIFIC CORP | N/A | 21.82M | ||
| MDX.CA | MEDX HEALTH CORP | N/A | 18.53M | ||
| VPT.CA | VENTRIPOINT DIAGNOSTICS LTD | N/A | 15.93M | ||
| THRM.CA | THERMA BRIGHT INC | N/A | 3.41M | ||
| VER-H.CA | VERISANTE TECHNOLOGY INC | N/A | 439.40K | ||
| VVTM.CA | VVT MED INC | N/A | 18.71M |
Related stock screener links
About TLT.CA
Company Profile
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in Toronto, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. The company operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Company Info
THERALASE TECHNOLOGIES INC
41 Hollinger Road
TORONTO ONTARIO M4B 3G4 CA
CEO: Shawn Shirazi
Employees: 20
Phone: 14166995273
THERALASE TECHNOLOGIES INC / TLT.CA FAQ
What does THERALASE TECHNOLOGIES INC do?
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in Toronto, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. The company operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
What is the stock price of THERALASE TECHNOLOGIES INC today?
The current stock price of TLT.CA is 0.205 CAD. The price increased by 2.5% in the last trading session.
Does THERALASE TECHNOLOGIES INC pay dividends?
TLT.CA does not pay a dividend.
How is the ChartMill rating for THERALASE TECHNOLOGIES INC?
TLT.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is THERALASE TECHNOLOGIES INC (TLT.CA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TLT.CA.
Is THERALASE TECHNOLOGIES INC (TLT.CA) expected to grow?
The Revenue of THERALASE TECHNOLOGIES INC (TLT.CA) is expected to grow by 17.72% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
TLT.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to TLT.CA. When comparing the yearly performance of all stocks, TLT.CA is a bad performer in the overall market: 90.88% of all stocks are doing better.
TLT.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TLT.CA. TLT.CA may be in some trouble as it scores bad on both profitability and health.
TLT.CA Financial Highlights
Over the last trailing twelve months TLT.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 27.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -141.86% | ||
| ROE | -335.23% | ||
| Debt/Equity | 0.13 |
TLT.CA Forecast & Estimates
9 analysts have analysed TLT.CA and the average price target is 0.71 CAD. This implies a price increase of 248.29% is expected in the next year compared to the current price of 0.205.
For the next year, analysts expect an EPS growth of 39.41% and a revenue growth 17.72% for TLT.CA